System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Tabassum Wadasadawala is an expert in Oncology at Tata Memorial Hospital (India). As of July 2026, ScienceLeadR ranks Tabassum Wadasadawala in the top 1% of experts in India for Breast Neoplasms and Breast Diseases. Tabassum Wadasadawala has authored 129 publications, the most recent in 2026, and is an investigator in 2 clinical trials, 1 of them ongoing. SLR score: 344 (community average: 125). How the SLR is computed.

LeadR Profile

Tabassum Wadasadawala Tata Memorial Hospital India
344 ScienceLeadR Reputation 344

Unlock

Register Login
Network Map

Oncology

Subspecialties: Radiotherapy - Public Health - Surgery

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2008 - 2026
Source: PubMed

Tata Memorial Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 129

Citations

Citations: 1 000 1st author: 39 Last author: 6 Unique author: 0

Main journals

Radiother Oncol 14
Clin Oncol (R Coll Radiol) 7
Int J Radiat Oncol Biol Phys 7
J Contemp Brachytherapy 7
Brachytherapy 6

Best Journals

Ann Oncol 2
J Clin Oncol 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Validation of Onco-MPI and Geriatric-8 for predicting 2-year mortality in older Indian patients with breast cancer: a prospective observational study.
PMID 42389560 — mortality, breast neoplasms, nomograms, neoplasms, breast, multivariate analysis, geriatric assessment, therapeutics		Ecancermedicalscience20260
Safety and Early Outcomes of Immediate Autologous Breast Reconstruction in Advanced Breast Cancer: An Indian Experience.
PMID 42316940 — comorbidity, safety, breast neoplasms, neoplasms, mammaplasty, breast, multivariate analysis, morbidity, therapeutics		Eur J Breast Health20260
Concordance of conventional two-tier HER2 classification versus three-tier classification (including HER2-low status) in invasive breast carcinoma: a retrospective real-world analysis.
PMID 42191357 — pathology, clinical, breast neoplasms, classification, breast, therapeutics		J Clin Pathol20260
The Extent of Indebtedness among Breast Cancer survivors in India: A Prospective Longitudinal Study from a Tertiary Cancer Hospital.
PMID 41759578 — cancer survivors, longitudinal studies, breast neoplasms, neoplasms, income, breast, therapeutics, medical oncology		J Cancer Policy20260
In Reply to Sourial et al.
PMID 41545097 — radiobiology		Int J Radiat Oncol Biol Phys20260

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 2

By status:

Recruiting 2

By type:

Interventional 1
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 1
multicentricup10 0

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Assessment of the Breast Cosmesis Using Deep Neural Networks an Exploratory Study (ABCD)
NCT05450016 — breast neoplasms, neoplasms, breast, therapeutics		N/ARecruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS